Market closedNon-fractional
Lucid Diagnostics/LUCD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Ticker
LUCD
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
New York, United States
Employees
70
Website
www.luciddx.com
LUCD Metrics
BasicAdvanced
$45M
Market cap
-
P/E ratio
-$1.27
EPS
1.48
Beta
-
Dividend rate
Price and volume
Market cap
$45M
Beta
1.48
Financial strength
Current ratio
1.381
Quick ratio
1.329
Long term debt to equity
1.488
Total debt to equity
119.203
Interest coverage (TTM)
-113.82%
Management effectiveness
Return on assets (TTM)
-69.23%
Return on equity (TTM)
-255.60%
Valuation
Price to revenue (TTM)
12.187
Price to book
-1.24
Price to tangible book (TTM)
-1.2
Price to free cash flow (TTM)
-0.943
Growth
Revenue change (TTM)
370.50%
Earnings per share change (TTM)
-20.23%
3-year earnings per share growth (CAGR)
22.81%
What the Analysts think about LUCD
Analyst Ratings
Majority rating from 6 analysts.
LUCD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
0.00%
Net income
-$11M
-1.85%
Profit margin
-1,060.00%
-1.85%
LUCD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.27
-$0.34
-$0.25
-$0.40
-
Expected
-$0.32
-$0.27
-$0.26
-$0.27
-$0.23
Surprise
-15.89%
24.77%
-3.03%
49.25%
-
LUCD News
AllArticlesVideos
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
PRNewsWire·4 days ago
Lucid Diagnostics Launches New Corporate Website
PRNewsWire·2 weeks ago
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
PRNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lucid Diagnostics stock?
Lucid Diagnostics (LUCD) has a market cap of $45M as of July 27, 2024.
What is the P/E ratio for Lucid Diagnostics stock?
The price to earnings (P/E) ratio for Lucid Diagnostics (LUCD) stock is 0 as of July 27, 2024.
Does Lucid Diagnostics stock pay dividends?
No, Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lucid Diagnostics dividend payment date?
Lucid Diagnostics (LUCD) stock does not pay dividends to its shareholders.
What is the beta indicator for Lucid Diagnostics?
Lucid Diagnostics (LUCD) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Lucid Diagnostics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.